The "Exosomes Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The exosome market is projected to register a CAGR of 27.89% during the forecast period, with a revenue of approximately USD 174.04 million in 2020.
Danaher Corporation (Beckman Coulter Inc.)
Fujifilm Holdings Corporation
Lonza Group Ltd
JSR Corporation (MBL international)
Bio-Techne (Novus Biologicals)
Thermo Fisher Scientific Inc.
Takara Bio Company
Key Market Trends
The Therapeutic Application Segment is Expected to Hold the Largest Market Share in the Exosomes Market
Exosomes have the capability to serve as a therapeutic platform for many diseases including COVID-19. Exosomes have clinical applications as cell-free alternatives for several disease treatment and tissue regeneration with the help of delivering therapeutic cargo components while circumventing immune rejection and cellular toxicity. In addition stemcell-derived exosomes are advantageous in harnessing the anti-inflammatory and regenerative abilities of parent cells thus exosomal treatment can be engineered for respiratory viral disease including SARS-CoV-2.
Exosomes have promising potential to be as a vehicle for drug delivery as they have natural material transportation properties, the capability of intrinsic long-term circulation, and high biocompatibility, which are the most suitable factors for the delivery of a variety of proteins, chemicals, and nucleic acids. According to a few research studies, exosomes have generated positive results as mediators of the intercellular communication, potentially delivering the functional proteins, mRNA transcripts, and miRNAs to cells throughout the body. Exosomes which are derived from some types of cells such as dendritic and mesenchymal stem cells have potential therapeutic properties and are biocompatible and efficient agents against various disorders such as organ injury. Although there is rapid progress in the research of exosome applications, there are many challenges in the development of exosome-based therapeutics, particularly in the production of the exosome formulations due to their low productivity and heterogeneity and also there are few barriers in the storage, optimizing and isolation methods of exosome formulations
North America Dominates the Market and is Expected to do the Same in the Forecast Period
During the COVID-19, the United States is the most affected country across the world, as the exosomes, extracellular vesicles are considered as potential mediators of infection, reinfection, and reactivation, and the growing number of research with respect to exosomes are positively impacting the market growth in North America.
The North American region holds one of the largest shares in the exosomes market, owing to better healthcare infrastructure, effective government policies, a huge base of multinational companies, and high awareness among people about diagnostics and healthcare. A large number of government-funded research studies have been conducted, regarding the role of drugs using exosomes in several kinds of cancers, such as melanoma, breast cancer, lung cancer, and pancreatic cancer, among others. Companies, like Merck and Exosome Diagnostic, have sponsored and collaborated with several universities, such as Yale University and Michigan State University, to conduct clinical trials in the United States. Furthermore, these ventures are very well supported by government funding. The studies were mostly conducted for neoplasm.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer
4.2.2 Technological Advancements in Exosomes Isolation and Analytical Procedures
4.2.3 Increasing Advanced Applications of Exosomes
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirement for Approval and Commercialization of Exosome Products
4.3.2 Technical Difficulties with the Implementation and Usage of Exosomes
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product
5.2 By Application
5.3.1 North America
5.3.4 Middle East and Africa
5.3.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Danaher Corporation (Beckman Coulter Inc.)
6.1.2 Diagenode Inc.
6.1.3 Fujifilm Holdings Corporation
6.1.4 Hitachi LTD
6.1.5 Lonza Group Ltd
6.1.6 JSR Corporation (MBL international)
6.1.7 Miltenyi Biotec
6.1.8 Bio-Techne (Novus Biologicals)
6.1.10 Thermo Fisher Scientific Inc.
6.1.11 Illumina, Inc.
6.1.12 Takara Bio Company
6.1.13 Malvern Instruments Ltd.
6.1.14 BioVision Inc
6.1.15 New England Peptide, Inc.
6.1.16 BioCat GmbH
6.1.17 Evox Therapeutics
6.1.20 Capricor Therapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/ovn89d
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005293/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900